| 6.25 -0.12 (-1.88%) | 04-23 12:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.04  |
1-year : | 11.73 |
| Resists | First : | 8.6 |
Second : | 10.04 |
| Pivot price | 4.42 |
|||
| Supports | First : | 5.23 |
Second : | 3.16 |
| MAs | MA(5) : | 5.69 |
MA(20) : | 4.28 |
| MA(100) : | 7.33 |
MA(250) : | 14.08 |
|
| MACD | MACD : | 0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 79.1 |
D(3) : | 79.5 |
| RSI | RSI(14): 72.2 |
|||
| 52-week | High : | 30.48 | Low : | 3.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ RGC ] has closed above the upper band by 3.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 64.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.44 - 6.46 | 6.46 - 6.48 |
| Low: | 5.6 - 5.62 | 5.62 - 5.64 |
| Close: | 6.4 - 6.43 | 6.43 - 6.47 |
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Wed, 17 Apr 2024
What Is The Ownership Structure Like For Regencell Bioscience Holdings Limited (NASDAQ:RGC)? - Yahoo Movies UK
Sun, 03 Mar 2024
RGC Stock Quote Price and Forecast - CNN
Sun, 07 Jan 2024
Regencell Bioscience Holdings Limited (NASDAQ:RGC) CEO Yat-Gai Au's holdings dropped 16% in value as a result ... - Yahoo Finance
Mon, 03 Apr 2023
Anyone, Anywhere, You Can Make A Difference! - ValueWalk
Mon, 12 Sep 2022
Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim ... - Business Wire
Mon, 16 May 2022
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 13 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 88.7 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.92 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.6 % |
| Return on Equity (ttm) | -41.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -14.56 |
| PEG Ratio | 0 |
| Price to Book value | 7.11 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|